Replies to post #195977 on Anavex Life Sciences Corp (AVXL)

[bennyboy1]

Greenspam3: Thanks so much for the new patents filed - one for visceral and neuropathy PAIN - another for BLOOD PRESSURE REGULATION!!! Looks like Dr Missling intends to become a BIG WHALE looking for BIG INDICATIONS!!! Full speed ahead, that is the gist of it!!!! There is no telling how many indications 2-73 and AV-1066 and others will eventually be covered. Also shows strong confidence our CEO Missling has in ANAVEX and the ANAVEX PIPELINE!!!!!!!!!!!!!!!!

[LakeshoreLeo1953]

This application claims priority to U.S. provisional application number 62/591,248, filed November 28, 2017, the entire disclosure of which is herein incorporated by reference.

[nidan7500]

Nice things happen when actual hard data is available. And, since sleep is mentioned again I sure hope they are using one of those sleep monitoring FDA validated gadget thingees. Like the Actigraph gadget and even the AI Cognision thingee.

http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019108653&tab=PCTBIBLIO&office&prevFilter&sortOption=Pub+Date+Desc&queryString=FP%3A%28anavex%29&recNum=2&maxRec=38&fbclid=IwAR1R-6LmOI1qaWSmh1gixjbLF6qLMAuhqT2mS-DT173ea-5uiJId_DNz6iA

[0024] Thirty -two Alzheimer’s disease patients took part in the phase Ila trial.
Mean age was 69.5 (standard deviation [SD] 9.8) years, 60% were male, mean body mass index was 26.5 (SD 3.9) kg/m2, and 50% were on antihypertensive medication at the time of screening. In unadjusted analyses, there was a significant decline in SBP comparing the first measurement (mean SBP 143.3, SD 19.7, mmHg) to all subsequent measurements (p=0.007, 0.001, and 0.007, respectively). There was a mean 8.7 (SD 3.0) mmHg SBP decline between the first and second measurements (i.e.. immediately prior to the first treatment), but no significant decline comparing the second measurement to all subsequent measurements (p=0. l20 and 0.972, respectively). In multivariable adjusted models (Fig. 1), there was no significant difference in SBP between the first and second readings (p=0.2l 1). There was, however, a significant decline in SBP between the first reading and the other subsequent readings (p=0.048 and 0.008, respectively), as shown in Fig. 1. Of note, no patients reported any changes in their antihypertensive regimen while taking part in the trial.

[0025] No previous reports were found of a decline in SBP following treatment with a sigma- 1 receptor agonist. This class of medications thus provides a novel mechanism for systolic BP reduction useful in treating isolated systolic hypertension. The efficacy of A2-73 is presented graphically in Fig. 1, presenting repeated systolic BP readings across visits, adjusted for time of BP measurement, gender, age, body mass index, and use of antihypertensive medication. The beneficial effect of lowering systolic blood pressure included patients exhibiting resistance to many of the existing classes of anti-hypertensive drugs and thus represents a significant advance is the treatment of high systolic blood pressure.

[falconer66a]

A Second Patent

...which reduces blood pressure (now, another application for Anavex 2-73).

Hypertension (high blood pressure) is a major pathology. Gigantic market.